Veradermics Inc (MANE)

Currency in USD
124.91
+6.66(+5.63%)
Closed·
124.910.00(0.00%)
·
MANE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
116.19125.32
52 wk Range
32.00131.24
Key Statistics
Prev. Close
118.25
Open
118.42
Day's Range
116.19-125.32
52 wk Range
32-131.24
Volume
260.68K
Average Volume (3m)
663.13K
1-Year Change
-
Book Value / Share
10.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MANE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
141.60
Upside
+13.36%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Veradermics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 141.60
(+13.36% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy---MaintainJun 25, 2026
LifeSci Capital
Buy135.00+8.08%-New CoverageJun 16, 2026
Needham
Buy136.00+8.88%-New CoverageJun 02, 2026
Jefferies
Buy138.00+10.48%111.00MaintainApr 30, 2026
Citi
Buy120.00-3.93%85.00MaintainApr 27, 2026

Earnings

Latest Release
May 12, 2026
EPS / Forecast
-1.20 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MANE Income Statement

Compare MANE to Peers and Sector

Metrics to compare
MANE
Peers
Sector
Relationship
P/E Ratio
−52.8x−0.4x−0.4x
PEG Ratio
-−0.420.00
Price/Book
13.4x2.4x2.6x
Price / LTM Sales
-4.5x3.0x
Upside (Analyst Target)
14.2%20.3%51.9%
Fair Value Upside
Unlock2.4%9.4%Unlock

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Employees
24

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.91M14.14%698.47M
Other Institutional Investors
40.65M85.86%4.81B
Public Companies & Retail Investors
0.000.00%0.00
Total
46.56M100.00%5.51B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Longitude Capital Management Co., LLC11.14%4,653,873550,320
Suvretta Capital Management, LLC9.98%4,168,970492,981

People Also Watch

18.80
LIFE
-0.53%
73.32
CGON
+5.04%
36.510
CUE
+3.28%
41.30
INDV
+1.00%
19.180
ERAS
+1.64%

FAQ

What Is the Veradermics (MANE) Stock Price Today?

The Veradermics stock price today is 124.91 USD.

What Stock Exchange Does Veradermics Trade On?

Veradermics is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Veradermics?

The stock symbol for Veradermics is "MANE."

What Is the Veradermics Market Cap?

As of today, Veradermics market cap is 4.94B USD.

What Is Veradermics's Earnings Per Share (TTM)?

The Veradermics EPS (TTM) is -15.84.

When Is the Next Veradermics Earnings Date?

Veradermics will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is MANE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Veradermics Stock Split?

Veradermics has split 0 times.

How Many Employees Does Veradermics Have?

Veradermics has 24 employees.

What is the current trading status of Veradermics (MANE)?

As of Jul 09, 2026, Veradermics (MANE) is trading at a price of 124.91 USD, with a previous close of 118.25 USD. The stock has fluctuated within a day range of 116.19 USD to 125.32 USD, while its 52-week range spans from 32.00 USD to 131.24 USD.

What Is Veradermics (MANE) Price Target According to Analysts?

The average 12-month price target for Veradermics is 141.60 USD, with a high estimate of 182 USD and a low estimate of 120 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +13.36% Upside potential.

What Is the MANE Premarket Price?

MANE's last pre-market stock price is 118.15 USD. The pre-market share volume is 1,090.00, and the stock has decreased by -0.10, or -0.08%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.